ArticleFrontiers in neurology2021

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center.

Marina Boziki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.